Xeris Biopharma Holdings, Inc.
NASDAQ:XERS · NASDAQ Global Select
+$0.04 today
Vol 1.95M · Avg 1.66M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $554.0K +101.0% | -$54.8M +11.9% | -$62.3M +34.2% | -$94.7M +22.9% | -$122.7M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $12.2M -3.7% | $12.6M -4.1% | $13.2M +3.9% | $12.7M +574.2% | $1.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 +100.0% | -$2.3M -81.6% | -$1.2M +12.3% | -$1.4M +0.0% | -$1.4M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $22.4M +21.8% | $18.4M +71.4% | $10.7M -11.9% | $12.2M +6.8% | $11.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$10.4M -17.5% | -$8.8M -40.1% | -$6.3M +82.1% | -$35.1M -396.5% | $11.9M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$10.6M -773.2% | -$1.2M +85.4% | -$8.4M +37.4% | -$13.4M +0.0% | -$13.4M | $592.6M | $1.3B | $626.2M |
| Inventory | -$19.3M -119.6% | -$8.8M +40.7% | -$14.8M -98.3% | -$7.5M +0.0% | -$7.5M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$69.0K +99.3% | -$9.6M -238.1% | $7.0M +261.2% | -$4.3M +0.0% | -$4.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $19.6M +81.9% | $10.8M +8.8% | $9.9M +199.2% | -$10.0M -150.0% | $20.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $3.9M +291.2% | -$2.0M -85.7% | -$1.1M -131.3% | $3.5M +0.4% | $3.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $28.6M +177.4% | -$37.0M +21.4% | -$47.0M +54.3% | -$102.9M +0.0% | -$102.9M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$696.0K +19.8% | -$868.0K +61.6% | -$2.3M -331.9% | -$524.0K +0.0% | -$524.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 -100.0% | $38.5M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 +100.0% | -$34.5M +21.2% | -$43.7M | $0 +100.0% | -$43.0M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 -100.0% | $40.2M +0.6% | $40.0M +14.3% | $35.0M +0.0% | $35.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 -100.0% | $4.6M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$696.0K -114.3% | $4.9M +181.3% | -$6.0M -117.4% | $34.5M +0.0% | $34.5M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $9.2M -76.0% | $38.2M | $0 -100.0% | $102.7M | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $13.1M | $0 -100.0% | $581.0K -98.1% | $30.0M +11.1% | $27.0M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$10.9M -191.3% | -$3.7M -270.1% | -$1.0M -115.6% | -$468.0K +12.4% | -$534.0K | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $1.7M +386.9% | -$604.0K +87.4% | -$4.8M | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $11.4M -68.5% | $36.2M +2342.3% | -$1.6M -101.3% | $127.5M +367.8% | $27.2M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 +100.0% | -$4.3M -144833.3% | -$3.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $39.3M +866.1% | $4.1M +107.4% | -$54.6M -192.5% | $59.0M +0.0% | $59.0M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $27.9M +173.8% | -$37.8M +23.2% | -$49.3M +52.3% | -$103.4M +0.0% | -$103.4M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.49B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.19B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.92B
BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
$1.90B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.67B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.65B
Immunocore Holdings plc
NASDAQ:IMCR
$1.45B
Biohaven Ltd.
NYSE:BHVN
$1.41B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.38B
Janux Therapeutics, Inc.
NASDAQ:JANX
$842.43M
SEC Filings
Recent regulatory filings
No filings found.
Does XERS generate free cash flow?
Xeris Biopharma Holdings, Inc. (XERS) generated $27.93M of free cash flow in fiscal 2025.
How much operating cash flow does XERS produce?
Operating cash flow was $28.63M, before capital expenditures of $696,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.